始めましょう
ReutersReuters

Immunic Announces Completion Of Enrollment For Both Phase 3 Ensure Trials In Relapsing MS And Presents Additional Data Underlining Positive Outcome Of Phase 2 Calliper Trial In Progressive MS

Refinitiv1分未満で読めます
IMUX

Immunic Inc IMUX:

  • IMMUNIC ANNOUNCES COMPLETION OF ENROLLMENT FOR BOTH PHASE 3 ENSURE TRIALS IN RELAPSING MS AND PRESENTS ADDITIONAL DATA UNDERLINING POSITIVE OUTCOME OF PHASE 2 CALLIPER TRIAL IN PROGRESSIVE MS

  • IMMUNIC INC - TOP-LINE DATA FOR PHASE 3 ENSURE TRIALS EXPECTED END OF 2026

Reuters米国株
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう

Reutersからその他のニュース